Literature DB >> 12606026

Trans-acting factors may cause dystrophin splicing misregulation in BMD skeletal muscles.

M Sironi1, R Cagliani, G P Comi, U Pozzoli, A Bardoni, R Giorda, N Bresolin.   

Abstract

We analyzed dystrophin alternative splicing events in a large number of Becker muscular dystrophy (BMD) affected individuals presenting major hot-spot deletions. Evidence is shown that altered splicing patterns in these patients do not directly result from the gene defect but probably derive from modifications in trans- rather than cis-acting factors. Several potential CUG-binding protein 2 (CUG-BP2) binding sites were found to be located in the dystrophin gene region encompassing exons 43-60 and CUG-BP2 transcript analysis indicated that not only expression levels are increased in dystrophic muscles but also that different CUG-BP2 isoforms are expressed. The possibility that CUG-BP2 might have a role in dystrophin splicing regulation is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606026     DOI: 10.1016/s0014-5793(03)00066-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

Review 1.  Normal and altered pre-mRNA processing in the DMD gene.

Authors:  Sylvie Tuffery-Giraud; Julie Miro; Michel Koenig; Mireille Claustres
Journal:  Hum Genet       Date:  2017-06-09       Impact factor: 4.132

2.  Hybrid spectrin type repeats produced by exon-skipping in dystrophin.

Authors:  Nick Menhart
Journal:  Biochim Biophys Acta       Date:  2006-04-19

3.  Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy.

Authors:  Andrea N Ladd; George Taffet; Craig Hartley; Debra L Kearney; Thomas A Cooper
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45.

Authors:  Andrew R Findlay; Nicolas Wein; Yuuki Kaminoh; Laura E Taylor; Diane M Dunn; Jerry R Mendell; Wendy M King; Alan Pestronk; Julaine M Florence; Katherine D Mathews; Richard S Finkel; Kathryn J Swoboda; Michael T Howard; John W Day; Craig McDonald; Aurélie Nicolas; Elisabeth Le Rumeur; Robert B Weiss; Kevin M Flanigan
Journal:  Ann Neurol       Date:  2015-03-02       Impact factor: 10.422

Review 5.  Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy.

Authors:  N Cohen; F Muntoni
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

6.  Differential stabilities of alternative exon-skipped rod motifs of dystrophin.

Authors:  Chris Ruszczak; Ahmed Mirza; Nick Menhart
Journal:  Biochim Biophys Acta       Date:  2009-03-12

7.  A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy.

Authors:  Ery Kus Dwianingsih; Rusdy Ghazali Malueka; Atsushi Nishida; Kyoko Itoh; Tomoko Lee; Mariko Yagi; Kazumoto Iijima; Yasuhiro Takeshima; Masafumi Matsuo
Journal:  J Hum Genet       Date:  2014-05-29       Impact factor: 3.172

8.  Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient.

Authors:  Kane Greer; Kayla Mizzi; Emily Rice; Lukas Kuster; Roberto A Barrero; Matthew I Bellgard; Bryan J Lynch; Aileen Reghan Foley; Eoin O Rathallaigh; Steve D Wilton; Sue Fletcher
Journal:  Mol Genet Genomic Med       Date:  2015-04-15       Impact factor: 2.183

9.  The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype.

Authors:  J Martone; F Briganti; I Legnini; M Morlando; E Picillo; O Sthandier; L Politano; I Bozzoni
Journal:  Nat Commun       Date:  2016-01-22       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.